Status Unknown
Clinical Application of a Novel 99mTc Labeled Fibroblast Activating Protein (FAP) Targeted Molecular Probe in Early Diagnosis of Tumors
Led by Nanjing First Hospital, Nanjing Medical University · Updated on 2025-03-11
20
Participants Needed
1
Research Sites
17 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
At present, radiopharmaceuticals targeting FAP have been developed for the diagnosis and treatment of various tumors. Considering the problems of fast tumor tissue clearance and short retention time in small molecule FAP inhibitors based on quinoline rings, this project optimized their ligands and developed a new FAP targeted technetium labeled molecular imaging probe for SPECT/CT imaging research to evaluate its safety in clinical application and its effectiveness in tumor diagnosis.
CONDITIONS
Brief Title
99mTc Labeled FAP Targeted Molecular Probe in Early Diagnosis of Tumors
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Voluntary subjects, patients or their legal representatives sign informed consent;
- Volunteers are of any gender and aged between 18 and 75 years old, including the cut-off value;
- Other imaging methods found tumor occupying;
- Patients with pre-treatment tumors for whom surgery or biopsy may be performed to obtain final pathological results.
- Kidney glomerular filtration rate(GFR)>50 ml/min, effective renal plasma flow(ERPF)>280 ml/min, platelet count (PLT) >75 000/μL, white blood cell (WBC) >3000/μL, alanine aminotransferase ALT, aspartate aminotransferase AST less than 3 times the normal value.
You will not qualify if you...
- People who have a history of allergy to similar drugs , allergic constitution or are currently suffering from allergic diseases;
- Is conducting clinical research on other drugs, or has participated in clinical research on any drugs (excluding vitamins and minerals);
- Have other clinical problems that are difficult to control (such as hepatitis C virus infection or active hepatitis B, or other serious chronic infections and serious mental, neurological, cardiovascular, respiratory and other diseases);
- Obvious abnormal liver and kidney function, GFR less than 50 ml/min;
- Tumor load is greater than 50%, or there is obvious spinal cord compression;
- The expected survival period is less than half a year; Chemotherapy was performed within 6 months.
- Have severe acute concomitant diseases or serious refractory mental disorders;
- Pregnant and lactating women (where pregnancy is defined as a positive urine pregnancy study);
- Patients whose physical condition is not suitable for radiological examination;
- Other situations deemed inappropriate by the investigator to participate in the trial.
Trial Site Locations
Total: 1 location
1
Nanjing First Hospital
Nanjing, Jiangsu, China, 210006
Actively Recruiting
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
0
Similar Trials
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here